Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study-Reference-Cited by-同舟云学术

Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study

Published:2012-03-16 Issue:5 Volume:27 Page:634-642
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:

Author:

Papp K.,Menter A.,Poulin Y.,Gu Y.,Sasso E.H.

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1468-3083.2012.04515.x/fullpdf

Reference26 articles.

1. Psoriasis: Is the impairment to a patient’s life cumulative?;Kimball;J Eur Acad Dermatol Venereol,2010

2. Risk of myocardial infarction in patients with psoriasis;Gelfand;JAMA,2006

3. Psoriasis comorbidities;Gottlieb;J Dermatolog Treat,2008

4. Effects of tumor necrosis factor-α blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis;Channual;Dermatol Therapy,2009

5. Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis;Kimball;Am J Med,2010

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis;Cochrane Database of Systematic Reviews;2023-07-12

2. Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial;British Journal of Dermatology;2023-01

3. English version of Japanese guidance for use of biologics for psoriasis (the 2022 version);The Journal of Dermatology;2022-12-29

4. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis;Cochrane Database of Systematic Reviews;2022-05-23

5. Adalimumab;TURKDERM;2022-05-05